Insurers want to know your biological age
Imagine you are 50 years old, but your biological age is 46. Would that mean a lower insurance premium? Life insurers are actively thinking about it.
Aging clocks, methods that estimate how old someone’s body is biologically, are drawing serious interest from the insurance sector. The analysts conclude that aging clocks work reasonably well at a population level, but remain too unreliable for individual commercial use. Two people with the same biological age of 46 can still differ substantially in health risk.
No gold standard in sight
The problem is fundamental: biological age has no universally accepted definition. Different clocks, based on DNA methylation (chemical modifications to DNA that change with age), protein profiles, or blood values, sometimes produce widely varying results for the same person. Insurers have used chronological age as a benchmark for centuries. It is simple, transparent, and legally defensible. Biological age is none of those things yet.
For the insurance industry, however, this is an existential question. If longevity therapies genuinely work and extend lives structurally, the mortality tables underpinning premiums will need complete revision. Whoever correctly anticipates this trend first holds a massive competitive advantage.
What clocks can and cannot do
Aging clocks are useful for population studies: they show whether an intervention slows biological aging on average. But an individual estimate, such as ‘aging at 0.7 years per year’, is not yet reliable enough to base life insurance decisions on. The readout can vary depending on which biomarkers are measured, which tissue is examined, and which algorithm is applied.
For longevity science, insurer interest is both a validation and an incentive. If the sector invests in better clocks, that could accelerate development of more reliable measurement tools. But the bar for individual precision is high, and it has not yet been cleared.
Search terms: DNA methylation clock individual variability, biological age measurement validity, mortality risk biomarkers